PATENT CLAIM ANALYSIS

Application Number: 15776043
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "230500"]

Abstract:
An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Claim (Index 13):
The method according to  claim 13 , wherein the nucleoside reverse transcriptase inhibitor is present and at least one member selected from the group consisting of Abacavir, Emtricitabine, Didanosine, Zidovudine, Apricitabine, Stampidine, Elvucitabine, Racivir, Amdoxovir, Stavudine, Tenofovir, Zalcitabine, and Festinavir.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.84906
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12709473', '12933757', '13640653', '14862875', '15231365']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.766354250560279
- 35 USC 102 Novelty (BERT): 0.4973444768323881
- Combined Prediction Score: 0.7394532731874899
- Mean Citation Score: 212.110914
- Max Citation Score: 219.36395
- Similarity Product: 170.25127293044324

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test